+26.9%
KRE vs MRNA
+945.0%
-918.1%
-15.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.7% | +13.1% | -11.4% | +1.8% |
| 7D | +2.8% | +20.6% | -17.8% | +3.0% |
| 30D | +5.3% | +27.1% | -21.8% | +5.6% |
| 3M | -4.2% | +353.4% | -357.6% | -2.9% |
| 6M | +8.7% | +446.3% | -437.6% | +8.3% |
| YTD | +16.4% | +776.2% | -759.8% | +11.9% |
| 1Y | +26.9% | +987.9% | -961.0% | +19.4% |
| All | +26.9% | +945.0% | -918.1% | +19.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling